(Q24201145)

2

0 references

Stephen J Milan

3

0 references

E. Haydn Walters

4

0 references

Parameswaran Nair

Cochrane Database of Systematic Reviews

5

0 references

publication date

13 January 2014

0 references

published in

0 references

cites work

A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Relationship between pretreatment specific IgE and the response to omalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab improves asthma-related quality of life in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Sputum hyaluronan and versican in severe eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Anti-IgE treatment: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Respiratory syncytial virus and recurrent wheeze in healthy preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

"Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effects of anti-IgE in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of omalizumab in health care workers with occupational latex allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Brain magnetic resonance imaging in adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Update on optimal use of omalizumab in management of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Effect of nebulized ipratropium on the hospitalization rates of children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Allergic inflammation in upper and lower airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Omalizumab: clinical use for the management of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Determinants of different dimensions of disease severity in asthma and COPD : pulmonary function and health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Immunologic basis of antigen-induced airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Anti-IgE for chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab reduces frequency of asthma exacerbations in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Predicting and evaluating response to omalizumab in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Relation between Airway Responsiveness and Serum IgE in Children with Asthma and in Apparently Normal Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

After 6 years with Xolair; a 3-year withdrawal follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Anti-IgE therapy for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021

l-Arginine Supplementation and Metabolism in Asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003559.PUB4

7 January 2021